Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.41 +5.53%

+$0.11 today

Market cap
$168.65M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 0.75M

Average 0.50M

PYXS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Pyxis Oncology, Inc.NASDAQ: PYXS

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 63.47M shares rose 4.0% year over year, ahead of the +2.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.1% from the prior quarter. Over 3 fiscal years it compounded at +23.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.0% holds above the trailing-twelve-month pace of +2.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
63.47M+2.1% QoQ
Last fiscal yearDec 2025
62.14M+6.3% YoY
LTMMar 2026
62.52M+2.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.0%——
1 year+6.3%——
3-year CAGR+23.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
62.14M USD
Year-over-year change
+6.3%
4-year CAGR
+17.8%

Weighted Avg Shares (Diluted) vs competitors

How PYXS compares with its peers on the latest reported figures

  • PYXS's LTM Mar 2026 weighted avg shares (diluted) of 62.52M shares is the 7th highest of the 10 companies compared; the peer median is 80.03M shares.
  • Its year-over-year change of +2.9% is the 7th highest of 10, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +23.4% compares with a peer median of +15.3%.
PYXS Competitors Peer median
Weighted Avg Shares (Diluted) for PYXS and competitors
Company Period LTM YoY 3-year CAGR
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.0%+15.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
Peer median (excluding PYXS) 80.03M+7.9%+15.3%

Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00016.15M13.86M
Cost of Revenue000475K2.39M
Gross Profit00015.67M11.47M
Gross Margin———97.1%82.8%
Research & Development51.05M86.13M49.59M58.75M73.7M
Selling, General & Admin18.66M37.35M32.61M25.42M22.19M
Operating Expenses69.72M123.48M82.2M105.13M95.89M
Depreciation & Amortization647K709K1.93M2.98M4.51M
EBITDA(75.33M)(120.01M)(71.86M)(65.51M)(73.72M)
EBITDA Margin———-405.8%-532.0%
Operating Income(69.72M)(123.48M)(82.2M)(89.46M)(84.42M)
Operating Margin———-554.1%-609.2%
Interest Income23K2.76M6.63M7.04M3.61M
Interest Expense00000
Other Income / Expenses(6.26M)2.76M8.41M9.97M6.19M
Income Before Tax(75.98M)(120.72M)(73.79M)(79.5M)(78.24M)
Pre-Tax Margin———-492.4%-564.5%
Income Tax Expense000(2.16M)1.39M
Net Income(75.98M)(120.72M)(73.79M)(77.33M)(79.62M)
Net Margin———-478.9%-574.5%
EPS (Basic)(2.53)(3.57)(1.85)(1.32)(1.28)
EPS (Diluted)(2.53)(3.57)(1.85)(1.32)(1.28)
Weighted Avg Shares32.22M33.03M39.9M58.45M62.14M
Weighted Avg Shares (Diluted)32.22M33.03M39.9M58.45M62.14M

Pyxis Oncology, Inc.

NASDAQ:PYXS

Intrinsic Alpha fair value

Locked

Current Price

$1.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.